Analysed SANA BIOTECHNOLOGY INC (SANA:NASDAQ) News Sources
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
11-05-2026
yahoo.com
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
12-05-2026
yahoo.com
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
15-05-2026
yahoo.com
‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic?
15-06-2026
euronews.com
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
01-07-2026
yahoo.com
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
13-07-2026
yahoo.com
What is the current price of SANA BIOTECHNOLOGY INC (SANA:NASDAQ)?
The current price of SANA BIOTECHNOLOGY INC (SANA:NASDAQ) is $3.17.
SANA BIOTECHNOLOGY INC (SANA:NASDAQ) absolute price change since previous trading day?
The absolute price change of SANA BIOTECHNOLOGY INC (SANA:NASDAQ) since the previous trading day is $0.
SANA BIOTECHNOLOGY INC (SANA:NASDAQ) percentage price change since previous trading day?
The percentage price change of SANA BIOTECHNOLOGY INC (SANA:NASDAQ) since the previous trading day is 0%.
What is the most recent average sentiment score for SANA BIOTECHNOLOGY INC (SANA:NASDAQ)?
The most recent average sentiment score for SANA BIOTECHNOLOGY INC (SANA:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for SANA BIOTECHNOLOGY INC (SANA:NASDAQ)?
The most recent sentiment for SANA BIOTECHNOLOGY INC (SANA:NASDAQ) is .
SEC-8K** Filing Available For SANA BIOTECHNOLOGY INC (SANA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.